Greenland Mines Ltd (GRML) Stock Price & Analysis
Greenland Mines Ltd (GRML) fell 3.52% to USD 0.3 as of June 10, 2026 at 07:08 UTC, according to Nexqual real-time market data.
GRML last closed at USD 0.31; the session ranged USD 0.27–0.31 on volume of 2,294,047 shares. Market capitalization is $36.26M, with a 52-week range of USD 0.21–2.45 (NCM). Source: Nexqual, June 10, 2026 at 07:08 UTC.
Key Statistics (as of June 10, 2026 at 07:08 UTC)
| Price | USD 0.3 |
|---|---|
| Change | ▼ 3.52% (down) |
| Previous Close | USD 0.31 |
| Open | USD 0.3 |
| Day Range | USD 0.27 – 0.31 |
| 52-Week Range | USD 0.21 – 2.45 |
| Volume | 2,294,047 shares |
| Market Cap | $36.26M |
| Exchange | NCM |
Technical Analysis (GRML)
Nexqual's technical model rates GRML "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.1 (neutral) |
| vs SMA50 | Below (USD 0.39) |
| MACD | -0.03 (negative) |
Analyst Ratings (GRML)
Wall Street analysts rate GRML "None", per Nexqual as of June 10, 2026 at 07:08 UTC.
| Consensus Rating | None |
|---|
Earnings (GRML)
Source: Nexqual, June 10, 2026 at 07:08 UTC.
Financials & Fundamentals (GRML)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -85.56% |
| Current Ratio | 19.74 |
| Total Cash | $10.00M |
| Total Debt | $0 |
| Free Cash Flow | $-5.53M |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
Financial Health Score (GRML)
Nexqual rates Greenland Mines Ltd's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -86%, ROA -30.0% |
Ownership (GRML)
| Insider Ownership | +17.18% |
|---|---|
| Institutional Ownership | +8.03% |
| Shares Outstanding | 121.24M |
| Float | 101.70M |
| Short % of Float | +6.53% |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
Leadership (GRML)
Greenland Mines Ltd is led by Joseph A. Sinkule Pharm.D. (age 71), Founder, CEO, Chairman of the Board & Secretary, per Nexqual as of June 10, 2026 at 07:08 UTC.
| Founder, CEO, Chairman of the Board & Secretary | Joseph A. Sinkule Pharm.D. (age 71) |
|---|---|
| Chief Financial Officer | Jeffrey LeBlanc (age 48) |
| Medical Advisor & Director | Shalom Z. Hirschman (age 89) |
| President | Bo Moller Stensgaard (age 50) |
| Chief Scientific Officer & Consultant | Miguel Chillon Rodriguez (age 59) |
Major Backers & Investors (GRML)
Notable institutional backers of Greenland Mines Ltd include Meteora Capital, LLC, UBS Group AG, Fidelity, according to Nexqual as of June 10, 2026 at 07:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Meteora Capital, LLC | 4.43% |
| UBS Group AG | 0.89% |
| Fidelity | 0.51% |
| Brummer Multi-Strategy AB | 0.31% |
| Two Sigma Securities, LLC | 0.17% |
| AM Investment Strategies, LLC | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.27% |
| Geode Capital | 0.61% |
| State Street | 0.16% |
| BlackRock | 0.12% |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
From Greenland Mines Ltd's Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- Our cell and gene therapy platform consists of proprietary technology programs (patents issued and pending) that include a gene therapy program that uses a gene therapy approach to produce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases and other diseases of aging (in-licensed pending patent applications from UAB).
Partnerships
- UAB and ICREA reserve the rights to use the licensed rights for internal non-commercial research and to allow other academic institutions to use the licensed rights for internal non-commercial research.    As set forth in the agreement, we are responsible for all costs associated with the research, development, and commercialization of the Products, including entering into a Sponsored Research agreement with Dr. Chillon's and Dr.
- Much of this work will be funded by the Sponsored Research Agreement with UAB in Barcelona.   Supplementation of this human Klotho protein by biologic infusion or by gene therapy may potentially treat many diseases and pathologies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCTI | Healthcare Triangle, Inc. | USD 2.36 | ▲ 4.42% |
| IXHL | Incannex Healthcare Inc. | USD 3.67 | ▲ 25.68% |
| PLRZ | Polyrizon Ltd. | USD 11.45 | ▼ 11.86% |
| CARM | Carisma Therapeutics, Inc. | USD 0 | ▲ 1,500% |
| NIVF | NewGenIvf Group Limited | USD 0.49 | ▼ 22.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:08 UTC. This page is informational and not investment advice.